IngredientesFlemingia philippinensis Merr. et Rolfe is the accepted binomial name for this species. It belongs to the family Fabaceae, subfamily Faboideae, tribe Phaseoleae, subtribe Cajaninae, and genus Flemingia. The species was originally described by Merrill and Rolfe. The plant also appears in the older literature under the synonym Moghania philippinensis — a name used in several phytochemical studies published primarily in the early 2000s, and referring to the same botanical entity.
Flemingia philippinensis (Merr. et Rolfe) is a shrubby herb belonging to the family Leguminosae; its roots are popularly used in traditional Chinese medicine. It is a Chinese herbal medicine rich in polyphenols, especially isoflavone derivatives, planted on a large scale, mainly distributed in Yunnan, Guizhou, Guangxi, and Sichuan provinces of China, and widely consumed by local residents as an important nutritional health product.
In the Chinese materia medica tradition, the dried root of the plant is known as Radix Flemingiae Philippinensis (千斤拔, qiān jīn bá in some regional nomenclature). Analytical studies of Radix Flemingiae Philippinensis have employed GC-MS and chemometric methods to characterize its volatile constituents.
The plant is a perennial shrub native to Southeast Asia, with a long-standing history of use in traditional medicine across the Philippines, China, and parts of India. Plants used in modern phytochemical investigations have been collected from farms in Guangxi province, China. In southern China, F. philippinensis is cultivated on a large scale and widely consumed by local inhabitants as an important nutraceutical for nutritious and therapeutic purposes, especially against rheumatism and associated inflammatory ailments.
The root (and root bark) is the primary plant part studied and used medicinally. Folk healers have traditionally employed its leaves, roots, and stems in decoctions to alleviate symptoms of rheumatism, arthritis, and general joint pain. In modern phytochemical research, extracts are typically prepared from dried roots using ethanol, methanol, dichloromethane, or aqueous solvents, and then fractionated by column chromatography. A 75% ethanolic extract of the roots has been used in isolation studies. Investigations of antioxidant potential have employed 0–80% ethanol extracts; the high-potency 80% ethanol extract recorded approximately 4,947 mg GAE/100 g total phenols, 3,058.1 mg QE/100 g total flavonoids, and 78% inhibition of DPPH at 100 μg/mL.
As a dietary supplement and nutraceutical ingredient, F. philippinensis is primarily encountered as a standardized root extract (typically in capsule or tablet form), a dried root powder, or as part of multi-herb TCM formulations. The plant has been widely cultivated for edible purposes and serves as a rich source of nutraceuticals and antioxidants.
The dry root of Flemingia philippinensis has been widely used in the treatment of rheumatism, arthropathy, and osteoporosis in traditional Chinese medicine; its therapeutic effects are associated with antiarthritis in TCM theory. Its roots are popularly used to treat rheumatism, arthropathy, leucorrhea, menalgia, menopausal syndrome, chronic nephritis, and osteoporosis in traditional Chinese medicine.
The roots of F. philippinensis are used as an important food ingredient and a valuable traditional Chinese medicine for the treatment of chronic nephritis, arthropathy, lumbar muscular strain, kala-azar, pain relief, leucorrhea, menalgia, menopausal syndrome, and related conditions. In traditional Chinese medicine, it is commonly blended with ingredients such as Achyranthes bidentata and Eucommia ulmoides to support joint and bone health.
As a traditional medicinal and edible plant originating from the Philippines, F. philippinensis has been widely applied in the treatment of various diseases, including chronic nephritis and rheumatoid arthritis. Additionally, it has demonstrated potential therapeutic effects in alleviating pain and improving certain gynecological conditions.
In addition to musculoskeletal ailments, Flemingia philippinensis has been used to treat skin conditions such as eczema, boils, and ulcers; the crushed leaves are often applied topically to soothe irritation and promote faster healing. In some regions, infusions made from the plant have been administered to address gastrointestinal issues, including diarrhea and intestinal parasites.
In China, the Philippines, and India, the roots, stems, and leaves of Flemingia philippinensis have been used for various ailments, including those related to the digestive system such as diarrhea, dysentery, and stomachaches. Within the broader Flemingia genus in the Indian subcontinent, related species are reported in traditional folklore medicine to treat tuberculosis, dysentery, leucorrhoea, epilepsy, insomnia, fever, diarrhea, scabies, swellings, ulcers, rheumatism, and skin diseases, and as a digestive, vermifuge, and to enhance lactation.
Ethnobotanical surveys and historical records indicate that various preparations of this plant — such as poultices or topical applications — have been employed by local healers to address bruising and reduce swelling.
Flemingia philippinensis belongs to the legume family and is a polyphenol-rich plant known in folk medicine and used to improve bone mineral density; its main bioactive constituents include flavanones, chalcones, isoflavones, steroids, and triterpenes, many of which have been proven to possess anti-inflammatory, anti-estrogenic, immunosuppressive, and antioxidant activities.
Prenylated isoflavones are the best-characterized and most pharmacologically active class of compounds. The series of plant-specific compounds with names beginning with "flemiphilippinin" are unique to this species and closely related taxa. Key isolates include:
Sixteen compounds isolated from the plant for neutrophil elastase inhibition studies were identified as nine prenylated isoflavones, three flavanones, three chalcones, and a flavonol. Investigation of roots also yielded two new chalcones — flemiphilippinones B and C — and one new pterocarpoid (demethylwedelolactone-11-methyl ether), together with 12 known compounds.
A new prenylated benzofuran derivative named flemiphilippinone A was isolated together with ten known flavonoids from the roots; its structure was established by HR EIMS, ¹H-NMR, ¹³C-NMR, HMQC, HMBC, and NOESY spectra.
The methanol extract of the root bark yielded eight PTP1B-inhibitory molecules, including three novel compounds — philippin A, B, and C — which possess a rare 3-phenylpropanoyl chromenedione skeleton.
Early studies on the chemical constituents of F. philippinensis revealed the presence of flavonoids, steroids, and triterpenes; subsequent research also isolated flavonoid glycosides, anthraquinones, and organic acids.
A GC-MS study of the volatile constituents of Radix Flemingiae Philippinensis identified 55 components accounting for 90.62% of total content; the main components were farnesol isomer and β-caryophyllene, accounting for 31.33% and 12.60% of total content, respectively.
A 2024 network pharmacology study obtained 29 active ingredients via data mining and identified five main active components for improving inflammation: flemichin D, naringenin, chrysophanol, genistein, and orobol. A total of 52 core protein targets were identified, including AKT serine/threonine kinase 1 (AKT1), tumor necrosis factor (TNF), B-cell lymphoma-2 (BCL2), serum albumin (ALB), and estrogen receptor 1 (ESR1).
F. philippinensis flavonoids (FPF) treatment suppressed the activation of NF-κB as indicated by downregulating the phosphorylation of NF-κB p65 and mitogen-activated protein kinases, and also significantly inhibited inflammation signaling by suppressing the activation of activator protein-1 subset and STAT3. KEGG enrichment analysis identified 149 relevant pathways, including those involved in EGFR tyrosine kinase inhibitor resistance, endocrine resistance, and the PI3K–Akt signaling pathway.
The plant has been used historically to cure rheumatism associated with neutrophil elastase (NE); sixteen NE-inhibitory flavonoids were isolated, including the most potent and abundant prenyl isoflavones, which competitively inhibited NE with IC50 values of 1.3–12.0 μM. They were reversible, simple, slow-binding inhibitors; the representative compound had IC50 = 1.3 μM, k3 = 0.04172 μM⁻¹ min⁻¹, k4 = 0.0064 min⁻¹, and Kiapp = 0.1534 μM, with Kik/Kiv ratios consistent with competitive inhibitors. The prenyl functionality of isoflavones significantly affected inhibitory potencies and mechanistic behavior by shifting the competitive mode to a noncompetitive one.
The methanolic extract from the roots showed significant effects on the proliferation of MCF-7 cells and induction of β-galactosidase activity in a yeast two-hybrid assay; the CHCl₃ fraction and its constituent 8-(1,1-dimethylallyl)genistein appreciably increased uterine weight in ovariectomized rats when administered orally for 14 consecutive days, with the compound showing stronger estrogenic activity than genistein. Through estrogenic activity-guided fractionation, several active prenylated flavonoids were isolated; 5,7,3',4'-tetrahydroxy-6,8-diprenylisoflavone showed the strongest antiestrogenic activity, and the ER-binding affinities of the isoflavonoids were not sufficiently high to explain their potent antagonistic activities, suggesting 17β-estradiol-non-competitive mechanisms.
The CH₂Cl₂ partition of a crude ethanolic extract from the roots showed potent aromatase inhibitory activity; five purified prenylated isoflavones were evaluated with IC50 values ranging between 2.98 and 58.08 μM; all behaved as reversible competitive inhibitors with Ki values calculated by Dixon plots; the most potent inhibitor, 6,8-diprenylorobol, had a Ki value of 1.42 μM and was proven to be present in native roots in high quantities by UPLC and LC/MS.
Xanthine oxidase is a frontier enzyme that produces oxidants leading to inflammation in the blood; prenylated isoflavones from F. philippinensis were found to display potent inhibition against XO, with all nine isolates inhibiting XO with IC50 ranging 7.8–36.4 μM; the most active isoflavones (compounds 2–5, IC50 = 7.8–14.8 μM) shared a catechol motif in the B-ring as a structural feature. The same compounds also showed potent anti-LDL oxidation effects in TBARS assay, the lag time of conjugated diene formation, relative electrophoretic mobility (REM), and fragmentation of apoB-100 on copper-mediated LDL oxidation.
PTP1B is an important target to treat obesity and diabetes due to its key roles in insulin and leptin signaling; the methanol extracts of the root bark of F. philippinensis yielded eight inhibitory molecules capable of targeting PTP1B. All eight compounds inhibited PTP1B in a dose-dependent manner with IC50s ranging between 2.4 and 29.4 μM; the most potent compound was prenylated isoflavone 5 (IC50 = 2.4 μM); chromenedione derivatives were reversible competitive inhibitors, whereas prenylated isoflavones were noncompetitive inhibitors.
The plant is a rich source of tyrosinase inhibitors; a 95% methanol extract of the roots exhibited good activity with 80% inhibition occurring at 30 μg/mL. The most potent inhibitor, a dihydrochalcone, showed significant inhibition against both monophenolase (IC50 = 1.28 μM) and diphenolase (IC50 = 5.22 μM) activities of tyrosinase; a flavanone possessing a resorcinol group also inhibited monophenolase (IC50 = 1.79 μM) and diphenolase (IC50 = 7.48 μM).
A total of 18 phenolic metabolite compounds were isolated and evaluated for antioxidant and DNA damage protection; antioxidant activity was screened using DPPH, ORAC, hydroxyl, and superoxide radical scavenging assays; most compounds showed good antioxidant potential; in particular, seven compounds showed significant protective effects on pBR322 plasmid DNA against the mutagenic and toxic effects of Fenton's reaction. The most active compound displayed a dose-dependent DNA damage protection potential in the range of 7.5–60.0 μM; the DNA damage protective effect was significantly correlated with hydroxyl radical scavenging activity, and compounds with effective (IC50 = 5.4–12.5 μg/mL) hydroxyl radical scavenging activity were found to have the highest DNA damage protection potential.
Bioactive metabolites of F. philippinensis possess anti-inflammatory, antiestrogenic, and immunosuppressive activities, including enzyme inhibitions against neuraminidase, tyrosinase, and protein tyrosine phosphatase. A coumestan compound with immunosuppressive activity has been isolated and published in Fitoterapia (Li et al., 2011), as cited across multiple reviews of the plant's pharmacology.
Traditional evidence: The plant has been used throughout history to cure rheumatism. It is well-known in folk medicine for use against rheumatism and to improve bone mineral density; in southern China it is widely consumed as a nutraceutical especially against rheumatism and associated inflammatory ailments.
Preclinical (animal) evidence: The strongest preclinical evidence relates to a collagen-induced arthritis (CIA) mouse model. A study investigated the mechanism of bone erosion protection and anti-inflammatory effect of F. philippinensis flavonoids (FPF) in CIA mice; flavonoids were extracted from the dry root, and C57BL/6 mice with CIA were orally fed with FPF prior to induction to mimic clinical prophylactic therapy for a total of 39 days. Mice with CIA were treated with 40 mg/kg FPF daily from day 7 to day 46. After treatment, FPF administration significantly suppressed paw swelling and arthritic score; FPF reduced inflammatory infiltration and pannus formation, articular cartilage destruction and osteoclast infiltration, and the expression of MMP-9 and cathepsin K in the ankle joint. FPF inhibited plasma anti-CII antibody levels and the production of inflammatory cytokines and chemokines; treatment suppressed the activation of NF-κB as indicated by downregulating phosphorylation of NF-κB p65 and mitogen-activated protein kinases; FPF also significantly inhibited inflammation signaling by suppressing activation of AP-1 and STAT3.
Evidence strength: Results showed FPF has therapeutic effects on CIA disease by regulating NF-κB and MAPK pathway proteins, and these results may provide evidence for future clinical application of FPF in the treatment of RA. However, the use of F. philippinensis for rheumatoid arthritis is supported primarily by traditional knowledge, with partial pharmacological rationale from in vitro studies; there is a significant gap in high-quality clinical evidence, and its efficacy and safety for RA in humans remains unproven. All evidence at this time is preclinical (animal/in vitro); no human clinical trials have been published.
Flemingia philippinensis, a polyphenol-rich plant, holds potential for improving inflammation, but its mechanisms have not been well understood; a 2024 study employed network pharmacology and molecular docking to explore the mechanism by which it ameliorates inflammation. Results showed that F. philippinensis had characteristics of multi-component, multi-target, and multi-pathway involvement in improving inflammation; however, while the results, based on database analysis and network visualization, show the effect of key components on improving inflammation, they lack data on the effect of drug dosage, and need further verification through cell and animal experiments. This is computational (in silico) evidence only and does not constitute human or animal trial data.
F. philippinensis has been widely applied in the treatment of various diseases including chronic nephritis and rheumatoid arthritis, and has demonstrated potential therapeutic effects in alleviating pain and improving certain gynecological conditions. The estrogenic and antiestrogenic activities have been demonstrated via in vitro MCF-7 cell proliferation assays and a yeast two-hybrid estrogen receptor assay (Ahn et al., 2004). The compound 8-(1,1-dimethylallyl)genistein appreciably increased uterine weight in ovariectomized rats when administered orally for 14 consecutive days, showing stronger estrogenic activity than genistein in that model.
Importantly, the plant has been used to improve rheumatism and bone mineral density, conditions which have deep correlations with oxidative stress.
Evidence strength: Limited to in vitro cell assays and one ovariectomized rat model. No human clinical trials on estrogenic, menopausal, or bone-mineral-density endpoints have been published for this plant.
A total of 18 phenolic compounds were isolated from F. philippinensis and their antioxidant activity was screened using DPPH, ORAC, hydroxyl, and superoxide radical scavenging assays. Seven of the identified compounds showed significant protective effects on pBR322 plasmid DNA against the mutagenic and toxic effects of Fenton's reaction. The most active compound displayed a dose-dependent DNA damage protection potential in the range of 7.5–60.0 μM; the DNA damage protective effect of the identified compounds was significantly correlated with hydroxyl radical scavenging activity.
Evidence strength: Entirely in vitro. These are biochemical assays; no human clinical evidence exists for antioxidant endpoints.
Work has investigated the antioxidant potential of prenylated isoflavones based on xanthine oxidase (XO) inhibition and anti-LDL oxidation. All nine isolates inhibited XO enzyme with IC50 ranging 7.8–36.4 μM; the most active isoflavones (IC50 = 7.8–14.8 μM) share a catechol motif in the B-ring. Existing research has indicated that the flavonoids in F. philippinensis extract not only have anti-inflammatory effects, but also a variety of biological activities such as anti-thrombosis, anti-oxidation, liver protection, and cardiovascular benefits.
Evidence strength: Entirely in vitro enzyme assays. No clinical cardiovascular data are available.
PTP1B is an important target for treating obesity and diabetes due to its key roles in insulin and leptin signaling; the methanol extract of the root bark of F. philippinensis yielded eight inhibitory molecules capable of targeting PTP1B. All compounds inhibited PTP1B in a dose-dependent manner with IC50s ranging between 2.4 and 29.4 μM; the most potent compound was prenylated isoflavone 5 (IC50 = 2.4 μM); the chromenedione derivatives were reversible competitive inhibitors, whereas prenylated isoflavones were noncompetitive inhibitors.
Evidence strength: Entirely in vitro. No animal or human studies on diabetes or obesity outcomes have been published for this plant extract.
Flemiphilippinone C, containing two prenyl groups, was extracted from the roots and showed antiproliferative activity against PC-3, Bel-7402, and CaEs-17 cancer cells with GI50 values of 14.12, 1.91, and 2.58 μM, respectively; it induces apoptosis in Bel-7402 cells by increasing S/G2 arrest via a specific mitochondria-related pathway. In vitro cytotoxicities of isolated compounds were determined against MCF-7, A549, and Hep-G2 cell lines by MTT assay; compound 1 (flemiphilippinin G) exhibited significant cytotoxicity against all tested cell lines with IC50 values of 4.8–7.3 μM. Flemiphilippinin A at 5 μg/mL also exhibited antitumor activity against human hepatocellular carcinoma cells (BEL-7402), human lung epithelial (A-549), and human ileocecal adenocarcinoma (HCT-8) with inhibition rates of 91.13%, 91.22%, and 79.77%, respectively.
Evidence strength: Entirely in vitro (cell-line studies). No in vivo animal studies or human clinical trials have been published on cancer outcomes for this plant or its extracts.
In efforts to find potential agents for the treatment of Alzheimer's disease in naturally occurring compounds, a systematic investigation for the active constituents of Flemingia philippinensis was carried out. All isolates were evaluated for their inhibition of self-induced Aβ aggregation; compound 5 showed notable Aβ aggregation inhibition with an inhibitory rate of 70.56%.
Evidence strength: In vitro Aβ aggregation assay only. This is preliminary, hypothesis-generating research with no clinical relevance demonstrated.
The prenylated isoflavones in this plant have predominantly been investigated for bacterial neuraminidase inhibition; chalcones and flavonoids have also shown strong inhibitory effects against tyrosinase. The in vitro tyrosinase inhibition data suggest potential relevance for hyperpigmentation or skin-related applications, but no clinical studies have been performed.
Ethnobotanical surveys and historical materia medica texts mention its use as a remedy for gastrointestinal discomfort and to help regulate bowel function; however, the scientific validation supporting these uses is limited; a few pharmacological studies have indicated that extracts of Flemingia species may have antidiarrheal or anti-inflammatory properties, but these studies are preliminary, often conducted in vitro or in animal models, and do not focus specifically on Flemingia philippinensis.
Based on the published phytochemical and pharmacological literature, F. philippinensis has been investigated in relation to the following body systems:
Research has indicated that the flavonoids in F. philippinensis extract not only have anti-inflammatory effects, but also a variety of biological activities such as anti-thrombosis, anti-oxidation, liver protection, and cardiovascular benefits.
No standardized human clinical dosage has been established for F. philippinensis. All dosage information in the peer-reviewed literature refers to experimental preparations used in laboratory or animal studies:
No formal human clinical trials, controlled safety studies, or systematic adverse event reporting specific to Flemingia philippinensis extracts or supplements have been identified in the peer-reviewed literature. No entries appear in the NIH Office of Dietary Supplements, NCCIH, WHO monographs, ESCOP, or the European Pharmacopoeia for this species.
The plant contains multiple compounds with demonstrated estrogenic and antiestrogenic activities. The root of F. philippinensis has been traditionally used for treating rheumatism, arthropathy, and chronic nephritis; the extract of the root has been shown to exhibit antioxidative, anti-inflammatory, estrogenic, and antiestrogenic activities. Individuals with hormone-sensitive conditions (such as hormone receptor-positive cancers) or those on hormone replacement therapies or anti-estrogenic drugs (e.g., tamoxifen, aromatase inhibitors) should be aware of this dual estrogenic/antiestrogenic profile, as it may alter hormone-dependent physiological processes.
Aromatase is the key enzyme responsible for catalyzing the conversion of C19 steroids to estrogens, and its inhibitors are widely used in breast cancer therapy; the CH₂Cl₂ partition of a crude ethanolic extract from the roots showed potent aromatase inhibitory activity. This raises potential for pharmacodynamic interaction with pharmaceutical aromatase inhibitors (e.g., anastrozole, letrozole) or with any hormone-regulating medication.
The roots of F. philippinensis contain flavonoids, especially prenylated isoflavones, which have shown anti-inflammation, antiestrogen, antitumor, cytotoxic, immunosuppressive, and antioxidant activities. The demonstrated immunosuppressive activity of isolated coumestan and isoflavone constituents suggests theoretical concern regarding co-administration with immunosuppressant drugs or in conditions where immune suppression would be harmful.
PTP1B plays key roles in insulin and leptin signaling. Given the in vitro PTP1B-inhibitory activity of root constituents, the theoretical potential exists for interaction with anti-diabetic medications (e.g., insulin, metformin, and other drugs targeting insulin signaling), though this has not been demonstrated in vivo.
F. philippinensis has been cultivated on a large scale and is widely consumed by local inhabitants as an important nutraceutical. Its long record of food and medicinal use in southern China and Southeast Asia suggests general tolerability at traditional dietary doses, but this does not substitute for formal toxicological evaluation of concentrated extracts or standardized supplements.
As of the available published literature, no regulatory body (NIH, NCCIH, WHO, EMA, EFSA, or equivalent) has issued a safety monograph, guidance document, or formal risk assessment for Flemingia philippinensis as a dietary supplement or herbal medicine. Pharmacopoeial standards specific to this species have not been identified in available sources.
The body of scientific literature on Flemingia philippinensis is composed entirely of in vitro biochemical studies and one murine (mouse) preclinical model. Network pharmacology findings based on database analysis lack data on the effect of drug dosage and need further verification through cell and animal experiments in the future. Animal model results may provide evidence for future clinical application of FPF in the treatment of RA but have not been translated into clinical trials. No randomized controlled trials, observational cohort studies, or any human clinical evidence exists for any health claim associated with this plant. All pharmacological findings should be regarded as preliminary and hypothesis-generating.
Condiciones de salud que Flemingia philippinensis puede ayudar a apoyar.
Sistemas corporales que Flemingia philippinensis puede ayudar a apoyar.
Volver